Thyroid cancer in clinical practice

Thyroid Cancer in Clinical Practice

Volumn , Issue , 2007, Pages 1-163

  McDougall, I Ross ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892138830     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-84628-748-0     Document Type: Book

References (479)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56(2):106-130.
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295(18):2164-2167.
3. Miller B, Kolonel LN, Bernstein L, et al. Racial/ethnic patterns of cancer in the United States 1988-1992. Bethesda, MD: National Institutes of Health, National Cancer Institute; 1996. Publication 96-4104.
4. Kendall-Taylor P. Managing differentiated thyroid cancer. BMJ 2002;324(7344):988-989.
5. Rybicki F, Nawfel RD, Judy PF, et al. Skin and thyroid dosimetry in cervical spine screening: two methods for evaluation and a comparison between a helical CT and radiographic trauma series. A J R Am J Roentgenol 2002;179(4):933-937.
6. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995;141(3):259-277.
7. Ron E, Saftlas AF. Head and neck radiation carcinogenesis: epidemiologic evidence. Otolaryngol Head Neck Surg 1996;115(5):403-408.
8. Hamilton P, Chiacchiernini RP, Kacmarek RG. A follow-up study of persons who had iodine-131 and other diagnostic procedures during childhood and adolescence. Rockville, MD: Health and Human Services, Food and Drug Administration; 1989. Publication 8208276.
9. Holm LE, Wiklund KE, Lundell GE, et al. Thyroid cancer after diagnostic doses of iodine-131: a retrospective cohort study. J Nad Cancer Inst 1988;80(14):1132-1138.
10. Dickman PW, Holm LE, Lundell G, Boice JD Jr, Hall P. Thyroid cancer risk after thyroid examination with 131I: a population-based cohort study in Sweden. Int J Cancer 2003;106(4):580-587.
11. Michel LA, Donckier JE. Thyroid cancer 15 years after Chernobyl. Lancet 2002;359(9321):1947.
12. Maxon HR, Saenger EL, Thomas SR, et al. Clinically important radiation-associated thyroid disease. A controlled study. JAMA 1980;244(16):1802-180S.
13. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med 1991;325(9):599-605.
14. Modan B, Ron E, Werner A. Thyroid cancer following scalp irradiation. Radiology 1977;123:741-744.
15. Ron E. Cancer risks from medical radiation. Health Phys 2003;85(1):47-59.
16. Inskip PD. Thyroid cancer after radiotherapy for childhood cancer. Med Pediatr Oncol 2001;36(5):568-573.
17. Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 1998;280(4):347-355.
18. Berrington A, Darby SC, Weiss HA, Doll R. 100 years of observation on British radiologists: mortality from cancer and other causes 1897-1997. Br J Radiol 2001;74(882):507-519.
19. Mohan AK, Hauptmann M, Freedman DM, et al. Cancer and other causes of mortality among radiologic technologists in the United States. Int J Cancer 2003;103(2):259-267.
20. Omar RZ, Barber JA, Smith PG. Cancer mortality and morbidity among plutonium workers at the Sellafield plant of British Nuclear Fuels. Br J Cancer 1999;79(7-8):1288-1301.
21. Blettner M, Zeeb H, Auvinen A, et al. Mortality from cancer and other causes among male airline cockpit crew in Europe. Int J Cancer 2003;106(6):946-952.
22. Prentice RL, Kato H, Yoshimoto K, Mason M. Radiation exposure and thyroid cancer incidence among Hiroshima and Nagasaki residents. Nat! Cancer Inst Monogr 1982;62:207-212.
23. Bouville A, Simon SL, Miller CW, Beck HL, Anspaugh LR, Bennett BG. Estimates of doses from global fallout. Health Phys 2002;82(5):690-705.
24. Roff SR. The glass bead game: nuclear tourism at the Australian weapon test sites. Med Confi Surviv 1998;14(4):290-302.
25. Conard RA, Dobyns BM, Sutow WW. Thyroid neoplasia as late effect of exposure to radioactive iodine in fallout. lama 1970;214:316-324.
26. Reynolds T. Final report of Hanford Thyroid Disease Study released. J Nat! Cancer Inst 2002;94(14):1046-1048.
27. Goldman M. The Russian radiation legacy: its integrated impact and lessons. Environ Health Perspect 1997;105(suppl 6):1385-1391.
28. Rabes HM. Gene rearrangements in radiation-induced thyroid carcinogenesis. Med Pediatr Oncol 2001;36(S):574-582.
29. Kazakov VS, Demidchik EP, Astakhova LN. Thyroid cancer after Chernobyl. Nature 1992;359(6390):21.
30. Baverstock K, Williams D. Chernobyl: an overlooked aspect? Science 2003;299(5603):44.
31. Mathew CG, Smith BA, Thorpe K, et al. Deletion of genes on chromosome 1 in endocrine neoplasia. Nature 1987;328(6130):524-526.
32. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RETproto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2(7):851-856.
33. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 1999;17(1):380-393.
34. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAFmutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88(11):5399-5404.
35. Takami H, Ozaki O, Ito K. Familial nonmedullary thyroid cancer: an emerging entity that warrants aggressive treatment. Arch Surg 1996;131(6):676.
36. Grossman RF, Tu SH, Duh QY, Siperstein AE, Novosolov F, Clark OH. Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment. Arch Surg 1995;130(8):892-897; discussion 898-899.
37. Pal T, Vogl FD, Chappuis PO, et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab 2001;86(11):5307-5312.
38. Frich L, Glattre E, Akslen LA. Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway. Cancer Epidemiol Biomarkers Prev 2001;10(2):113-117.
39. Malchoff CD, Malchoff DM. Familial nonmedullary thyroid carcinoma. Semin Surg Oncol 1999;16(1):16-18.
40. Bevan S, Pal T, Greenberg CR, et al. A comprehensive analysis of MNG1) TC01) fpTC, PTEN, TSHR, and TRKAin familial nonmedullary thyroid cancer: confirmation of linkage to TCOL J Clin Endocrinol Metab 2001;86(8):3701-3704.
41. Uchino S, Noguchi S, Kawamoto H, Yamashita H, Watanabe S, Shuto S. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg 2002;26(8):897-902.
42. Mack WI, Preston-Martin S, Dal Maso L, et al. A pooled analysis of case-control studies of thyroid cancer: cigarette smoking and consumption of alcohol) coffee, and tea. Cancer Causes Control 2003;14(8):773-785.
43. Ward JM, Ohshima M. The role of iodine in carcinogenesis. Adv Exp Med Biol 1986;206:529-542.
44. Peretz A, Leiberman E, Kapelushnik J, Hershkovitz E. Thyroglossal duct carcinoma in children: case presentation and review of the literature. Thyroid 2004;14(9):777-785.
45. Schmutzler C. Regulation of the sodium/iodide symporter by retinoids-a review. Exp Clin Endocrinol Diabetes 2001;109(1):41-44.
46. Darcan S, Goksen D. Consequences of iodine deficiency and preventative measures. Pediatric Endocrine Rev 2003;1:162-168.
47. Levy O, De La Vieja A, Carrasco N. The Na+/I-symporter (NIS): recent advances. J Bioenerg Biomembr 1998;30(2):195-206.
48. Russo D, Manole D, Arturi F, et al. Absence of sodium/iodide symporter gene mutations in differentiated human thyroid carcinomas. Thyroid 2001;11(1):37-39.
49. Persani I. Hypothalamic thyrotropin-releasing hormone and thyrotropin biological activity. Thyroid 1998;8:941-946.
50. Heuer H, Schafer MK, Bauer K. Thyrotropin-releasing hormone (TRH), a signal peptide of the central nervous system. Acta Med Austriaca 1999;26:119-122.
51. Zervas IM, Papakostas YG, Theodoropoulou MA, Dimitrakopoulos C, Vaidakis N, Daras M. Thyrotropin-releasing hormone administration does not affect seizure threshold during electroconvulsive therapy. J Ect 2003;19(3):136-138.
52. Choi YH, Hartzell D, Azain MJ, Baile CA. TRH decreases food intake and increases water intake and body temperature in rats. Physiol Behav 2002;77(1):1-4.
53. Szkudlinski MW, Fremont V, Ronin C, Weintraub BD. Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol Rev 2002;82(2):473-502.
54. Joshi L, Murata Y, Wondisford FE, Szkudlinski MW, Desai R, Weintraub BD. Recombinant thyrotropin containing a beta-subunit chimera with the human chorionic gonadotropin-beta carboxy-terminus is biologically active, with a prolonged plasma half-life: role of carbohydrate in bioactivity and metabolic clearance. Endocrinology 1995;136(9):3839-3848.
55. Szkudlinski MW, Thotakura NR, Bucci I, et al. Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity. Endocrinology 1993;133(4):1490-1503.
56. Pazos-Moura CC, Ortiga-Carvalho TM, Gaspar De Moura E. The autocrine/paracrine regulation of thyrotropin secretion. Thyroid 2003;13(2):167-175.
57. Berkowitz M, Daughtridge D, Sherwin JR. Autoregulation of thyroid iodide transport: possible mediation by modification in sodium cotransport. Am J Physiol 1981;240(1):E37-42.
58. Viera AJ. Thyroid function testing in outpatients: are both sensitive thyrotropin (sTSH) and free thyroxine (FT4) necessary? Fam Med 2003;35(6):408-410.
59. Demers LM, Spencer CA. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clin Endocrinol (Oxf) 2003;58(2):138-140.
60. Topliss D. Thyroid incidentaloma: the ignorant in pursuit of the impalpable. Clin Endocrinol (Oxt) 2004;60(1):18-20.
61. Ashcraft M, Van Herle AJ. Management of the thyroid nodule. Scanning techniques, thyroid suppressive therapy and fine-needle aspiration. Head Neck Surg 1981;3:297-322.
62. Wanet P, Sand A, Abramovici J. Physical and clinical evaluation of high-resolution thyroid pinhole tomography. J Nucl Med 1996;37:2017-2020.
63. Ahuja A, Chick W, King W, Metreweli C. Clinical significance of the comet-tail artifact in thyroid ultrasound. J Clin Ultrasound 1996;24(3):129-133.
64. Chan BK, Desser TS, McDougall IR, Weigel RJ, Jeffrey R B Jr. Common and uncommon sonographic features of papillary thyroid carcinoma. J Ultrasound Med 2003;22(10):1083-1 090.
65. Afroze N, Kayani N, Hasan S He Role of fine needle aspiration cytology in the diagnosis of palpable thyroid lesions. Indian J Pathol Microbiol 2002;45(3):241-246.
66. Agrawal S. Diagnostic accuracy and role of fine needle aspiration cytology in management of thyroid nodules. J Surg Oncol 1995;58(3):168-172.
67. Solomon D, Keeler EB. Cost-effective analysis of the evaluation of thyroid nodule. Ann Intern Med 1982;96:221-232.
68. Singer PA. Thyroid nodules: malignant or benign? Hosp Pract (Minneap) 1998;33(1):143-144, 147-148, 153-156.
69. Aguilar J, Rodriguez JM, Flores B, et al. Value of repeated fine-needle aspiration cytology and cytologic experience on the management of thyroid nodules. Otolaryngol Head Neck Surg 1998;119(1):121-124.
70. Logani S, Osei SY, LiVolsi VA, Baloch ZW. Fine-needle aspiration of follicular variant of papillary carcinoma in a hyperfunctioning thyroid nodule. Diagn Cytopathol 2001;25(1):80-81.
71. Gharib H, James EM, Charboneau JW, Naessens JM, Offord KP, Gorman CA. Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study. N Engl J Med 1987;317:70-75.
72. Castro MR, Caraballo PI, Morris JC. Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis. J Clin Endocrinol Metab 2002;87(9):4154-4159.
73. Nygaard B, Faber J, Hegedus I. Acute changes in thyroid volume and function following 1311 therapy of multinodular goitre. Clin Endocrinol (OxO 1994;41(6):715-718.
74. Bhagat MC, Dhaliwal SS, Bonnema SJ, Hegedus L, Walsh IP. Differences between endocrine surgeons and endocrinologists in the management of non-toxic multinodular goitre. Br I Surg 2003;90(9):1103-1112.
75. Nygaard B, Faber I, Veje A, Hegedus L, Hansen IM. Appearance of Graves'-like disease after radioiodine therapy for toxic as well as non-toxic multinodular goitre. Clin Endocrinol (OxO 1995;43(1):129-130.
76. Chiovato L, Santini F, Vitti P, Bendinelli G, Pinchera A. Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre. Clin Endocrinol (OxO 1994;40(6):803-806.
77. Verelst I, Bonnyns M, Glinoer D. Radioiodine therapy in voluminous multinodular non-toxic goitre. Acta Endocrinol (Copenh) 1990;122(4):417-421.
78. Manders JM, Corstens FH. Radioiodine therapy of euthyroid multinodular goitres. Eur J Nucl Med Mol Imaging 2002;29(suppl 2):S466-470.
79. Glinoer D. Radioiodine therapy of non-toxic multinodular goitre. Clin Endocrinol (Oxf) 1994;41(6):713-714.
80. Hartoft-Nielsen ML, Rasmussen AK, Friis E, et al. Unsuccessful radioiodine treatment of a non-toxic goiter: a case report. Basic Clin Pharmacol Toxicol 2004;95(2):72-75.
81. Nieuwlaat WA, Huysmans DA, Van Den Bosch HC, et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab 2003;88(7):3121-3129.
82. Duick DS, Baskin HJ. Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters. Endocr Pract 2003;9(3):204-209.
83. Hegedus L, Bonnema SI, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003;24(1):102-132.
84. Solymosi T, Gal I. Treatment of recurrent nodular goiters with percutaneous ethanol injection: a clinical study of twelve patients. Thyroid 2003;13(3):273-277.
85. Villanueva R, Haber R. Tracheal compression in a patient with substernal extension of a multinodular goiter. Thyroid 2000;10(4):367.
86. Fogelfeld L, Rubinstein U, Bar-On J, Feigl D. Severe thyrotoxicosis caused by an ectopic intrathoracic goiter. Clin Nucl Med 1986;11(1):20-22.
87. Erbil Y, Bozbora A, Barbaros U, Ozarmagan S, Azezli A, Molvalilar S. Surgical management of substernal goiters: clinical experience of 170 cases. Surg Today 2004;34(9):732-736.
88. Drivas I, Mansberg R, Roberts JM, Kean AM. Massive intrathoracic toxic multinodular goiter treated with radioiodine. Clin Nucl Med 2003;28(2):138-139.
89. Bonnema SJ, Knudsen DU, Bertelsen H, et al. Does radioiodine therapy have an equal effect on substernal and cervical goiter volumes? Evaluation by magnetic resonance imaging. Thyroid 2002;12(4):313-317.
90. Katlic MR, Grillo HC, Wang CA. Substernal goiter. Analysis of 80 patients from Massachusetts General Hospital. Am J Surg 1985;149(2):283-287.
91. McDougall I. Management of Thyroid Cancer and Related Nodular Disease. London: Springer-Verlag; 2006:95-133.
92. Nayar R, Frost AR. Thyroid aspiration cytology: a "cell pattern" approach to interpretation. Semin Diagn Pathol 2001;18(2):81-98.
93. Castro MR, Gharib H. Thyroid fine-needle aspiration biopsy: progress, pra ctice, and pitfalls. Endocr Pract 2003;9(2):128-136.
94. Ranchod M. Thyroid gland. In: Ranchod M, ed. Intraoperative Consultations in Surgical Pathology. Philadelphia: Hanley & Belfus; 1996:389-403.
95. Rosai J. Immunohistochemical markers of thyroid tumors: significance and diagnostic applications. Tumori 2003;89(5):517-519.
96. Nikiforov Y. Recent developments in the molecular biology of the thyroid. In: Lloyd RV, ed. Endocrine Pathology: Differential Diagnosis and Molecular Advances. Totowa, NJ: Human Press; 2004:191-209.
97. Rosai J, Carangiu ML, DeLellis RA, eds. Tumors of the Thyroid Gland. Washington) DC: Armed Forces Institute of Pathology; 1992:161-182.
98. Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumors. In: Hedinger CE, ed. International Histological Classification of Tumours. Vol 11. 2nd ed. Berlin: Springer-Verlag; 1988.
99. Williams E, Abrosimov A, Bogdanova T, et al. Two proposals regarding the terminology of thyroid tumors. Int J Surg Pathol 2000;8:181-183.
100. Brook I. Microbiology and management of acute suppurative thyroiditis in children. Int J Pediatr Otorhinolaryngol 2003;67(5):447-451.
101. Avram AM, Sturm CA, Michael CW, Sisson JC, Jaffe CA. Cryptococcal thyroiditis and hyperthyroidism. Thyroid 2004;14(6):471-474.
102. Kon YC, De Groot LJ. Painful Hashimoto's thyroiditis as an indication for thyroidectomy: clinical characteristics and outcome in seven patients. J Clin Endocrinol Metab 2003;88(6):2667-2672.
103. Weetman AP. Autoimmune thyroid disease. Autoimmunity 2004;37(4):337-340.
104. Liu LH, Bakhos R, Wojcik EM. Concomitant papillary thyroid carcinoma and Hashimoto's thyroiditis. Semin Diagn Pathol 2001;18(2):99-103.
105. Egsgaard Nielsen V, Hecht P, Krogdahl AS, Andersen PB, Hegedus I. A rare case of orbital involvement in Riedel's thyroiditis. J Endocrinol Invest 2003;26(10):1032-1036.
106. Rosai J, Kuhn E, Carcangiu ML. Pitfalls in thyroid tumour pathology. Histopathology 2006;49:107-120.
107. Li Volsi V. Surgical Pathology of the Thyroid. Philadelphia: WB Saunders; 1990:173.
108. Heppe H, Armin A, Calandra DB, Lawrence AM, Paloyan E. Hiirthle cell tumors of the thyroid gland. Surgery 1985;98(6):1162-1165.
109. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 1999;17(1):380-393.
110. Santoro M, Melillo RM, Carlomagno F, et al. Molecular biology of the MEN2 gene. J Intern Med 1998;243(6):505-508.
111. Souhami L, Simpson WJ, Carruthers JS. Malignant lymphoma of the thyroid gland. Int J Radiat Oncol BioI Phys 1980;6(9):1143-1147.
112. Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 1985;312(10):601-604.
113. MacDermed D, Thurber L, George TI, Hoppe RT, Le QT. Extranodal nonorbital indolent lymphomas of the head and neck: relationship between tumor control and radiotherapy. Int J Radiat Oncol Biol Phys 2004;59(3):788-795.
114. Kim NR, Ko YH, Sung CO. A case of coexistent angiosarcoma and follicular carcinoma of the thyroid. J Korean Med Sci 2003;18(6):908-913.
115. Craver RD, Lipscomb JT, Suskind D, Velez MC. Malignant teratoma of the thyroid with primitive neuroepithelial and mesenchymal sarcomatous components. Ann Diagn Pathol 2001;5(5):285-292.
116. De Ridder M, Sermeus AB, Urbain D, Storme GA. Metastases to the thyroid gland: a report of six cases. Eur J Intern Med 2003;14(6):377-379.
117. Giuffrida D, Ferrau F, Pappalardo A, et al. Metastasis to the thyroid gland: a case report and review of the literature. J Endocrinol Invest 2003;26(6):560-563.
118. Haraguchi S, Hioki M, Yamashita K, Orii K, Matsumoto K, Shimizu K. Metastasis to the thyroid from lung adenocarcinoma mimicking thyroid carcinoma. Jpn J Thorac Cardiovasc Surg 2004;52(7):353-356.
119. Heffess CS, Wenig BM, Thompson LD. Metastatic renal cell carcinoma to the thyroid gland: a clinicopathologic study of 36 cases. Cancer 2002;95(9):1869-1878.
120. Kihara M, Yokomise H, Yamauchi A. Metastasis of renal cell carcinoma to the thyroid gland 19 years after nephrectomy: a case report. Auris Nasus Larynx 2004;31(1):95-100.
121. Lam KY, Lo CY. Metastatic tumors of the thyroid gland: a study of 79 cases in Chinese patients. Arch Pathol Lab Med 1998;122(1):37-41.
122. Nakhjavani MK, Gharib H, Goellner JR, Van Heerden JA. Metastasis to the thyroid gland. A report of 43 cases. Cancer 1997;79(3):574-578.
123. Nakhjavani MM, Gharib M F H, Goellner MJ, Heerden M B C J A. Direct extension of malignant lesions to the thyroid gland from adjacent organs: report of 17 cases. Endocr Pract 1999;5(2):69-71.
124. Hay I, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institute during 1940 through 1989. Surgery 1993;114:1050-1058.
125. Shaha AR, Shah JP, Loree TR. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol 1997;4(4):328-333.
126. Shaha AR. Thyroid cancer: extent of thyroidectomy. Cancer Control 2000;7(3):240-245.
127. Mazzaferri E, Ihiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428.
128. Mazzaferri E. Radioiodine and other treatment and outcomes. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's The Thyroid. A Fundamental and Clinical Text. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2000:904-929.
129. Cady B. Presidential address: beyond risk groups-a new look at differentiated thyroid cancer. Surgery 1998;124(6):947-957.
130. Mazzaferri EL, Young RL, Oertel JE, et al. Papillary thyroid carcinoma: the impact of therapy on 576 patients. Medicine 1977;56:171-196.
131. Shaha A, Jaffe BM. Completion thyroidectomy: a critical appraisal. Surgery 1992;112:1148-1152.
132. Miccoli P, Iacconi P, Cecchini GM, et al. Thyroid surgery in patients aged over 80 years. Acta Chir Belg 1994;94(4):222-223.
133. Rosato L, Avenia N, Bernante P, et al. Complications of thyroid surgery: analysis of a multicentric study on 14, 934patients operated on in Italy over 5 years. WorId JSurg 2004;28(3):271-276.
134. Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583cases of thyroid carcinoma treated in the United States during 1996. U. S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000;89(1):202-217.
135. Williams M, Lo Gerfo P. Thyroidectomy using local anesthesia in critically ill patients with amiodarone-induced thyrotoxicosis: a review and description of the technique. Thyroid 2002;12(6):523-525.
136. Seidlin S, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. JAMA 1946;132:838-847.
137. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:458-460.
138. Smanik PA, Liu Q, Furminger TL, et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996;226(2):339-345.
139. Wapnir IL, Van De Rijn M, Nowels K, et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab 2003;88(4):1880-1888.
140. Goldman J, Line BR, Aamodt RL, et al. Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer. J Clin Endocrinol Metab 1980;50:734-739.
141. Brans B, Van Den Eynde F, Audenaert K, et al. Depression and anxiety during isolation and radionudide therapy. Nud Med Commun 2003;24(8):881-886.
142. Ladenson P, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888-896.
143. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84(11):3877-3885.
144. Paterakis T, Ebels H, Mallick UK, et al. Lack of antigenicity of recombinant human thyrotropin after multiple injections in patients with differentiated thyroid cancer. Thyroid 2000;10(7):623.
145. Durski JM, Weigel RJ, McDougall IR. Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer. Nud Med Commun 2000;21(6):521-528.
146. McDougall I, Weigel RJ. Recombinant human thyrotropin in the management of thyroid cancer. Curr Opin Oncol 2001;13:39-43.
147. Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 2002;9(4):227-247.
148. Robbins RJ, Robbins AK. Clinical review 156: recombinant human thyrotropin and thyroid cancer management. J Clin Endocrinol Metab 2003;88(5):19331938.
149. Westbury C, Vini L, Fisher C, Harmer C. Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin, Thyroid 2000;10(2):171-176.
150. McDougall JR. 74MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 1997;18:505-512.
151. Fatourechi V, Hay ID, Mullan BP, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 2000;10(7):573-577.
152. Park HM. 1231: almost a designer radioiodine for thyroid scanning. J Nucl Med 2002;43(1):77-78.
153. Yaakob W, Gordon L, Spicer KM, Nitke SJ. The usefulness of iodine-123 wholebody scans in evaluating thyroid carcinoma and metastases. J Nud Med Technol 1999;27(4):279-281.
154. Gulzar Z, Jana S, Young J, et al. Neck and whole-body scanning with 5-mCi dose of (123) 1 as diagnostic tracer in patients with well-differentiated thyroid cancer. Endocr Pract 2001;7(4):244-249.
155. Fenwick JD, Mallick UK, Perros P. 1231 imaging in the follow-up of differentiated thyroid cancer. Clin Oncol (R ColI Radiol) 2001;13(4):314.
156. Cohen JB, Kalinyak JE, McDougall IR. Clinical implications of the differences between diagnostic 1231and post-therapy 1311 scans. Nucl Med Commun 2004;25(2):129-134.
157. Perros P, Mallick UK, Fenwick JD. Radioiodine uptake in normal female breasts and liver of a patient with differentiated thyroid cancer imaged by whole body scanning. Thyroid 2003;13(5):51l.
158. McDougall IR. Whole-body scintigraphy with radioiodine-131. A comprehensive list of false positives with some examples. Clin Nucl Med 1995;20:869-875.
159. Carlisle M, Lu C, McDougall IR. The interpretation of 1311scans in the evaluation of thyroid cancer, with an emphasis on false positive findings. Nucl Med Commun 2003;24:715-735.
160. Davidson J, McDougall IR. How frequently is the thymus seen on whole-body iodine-131 diagnostic and post-treatment scans? Eur J Nucl Med 2000;27(4):425-430.
161. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83(4):1121-1127.
162. Ross D. Hyperthyroidism, thyroid hormone therapy and bone. Thyroid 1994;4:319-326.
163. Franklyn J, Betteridge J, Dykin J, et al. Long-term thyroxine treatment and bone mineral density. Lancet 1992;340:9-13.
164. Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal integrity. Ann Intern Med 1999;130(9):750-758.
165. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331(19):1249-1252.
166. Klein I, Danzi S. Evaluation of the therapeutic efficacy of different levothyroxine preparations in the treatment of human thyroid disease. Thyroid 2003;13:1127-1132.
167. Mandel SJ. Hypothyroidism and chronic autoimmune thyroiditis in the pregnant state: maternal aspects. Best Pract Res Clin Endocrinol Metab 2004;18(2):213-224.
168. McDougall IR, Maclin N. Hypothyroid women need more thyroxine when pregnant. J Fam Pract 1995;41(3):238-240.
169. Siegel E. The beginnings of radioiodine therapy of metastatic thyroid carcinoma: a memoir of Samuel M. Seidlin, M. D. (1895-1955) and his celebrated patient. Cancer Biother Radiopharm 1999;14(2):71-79.
170. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16(2):109-142.
171. Van Wyngaarden M, McDougall JR. What is the role of 1100MBq μ30m°C) radioiodine 131I in the treatment of patients with differentiated thyroid cancer? Nucl Med Commun 1996;17(3):199-207.
172. Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab 2004;89(4):1666-1673.
173. Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S. An analysis of "ablation of thyroid remnants" with 1-131 in 511 patients from 1947-1984: experience at University of Michigan. J Nucl Med 1984;25(12):1287-1293.
174. Hoyes KP, Owens SE, Millns MM, Allan E. Differentiated thyroid cancer: radioiodine following lobectomy-a clinical feasibility study. Nucl Med Commun 2004;25(3):245-251.
175. Massin JP, Savoie JC, Garnier H, Guiraudon G, Leger FA, Bacourt F. Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer 1984;53(4):982-992.
176. Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. I Nucl Med 1996;37:598-605.
177. McDougall I. Management of Thyroid Cancer and Related Nodular Disease. London: Springer-Verlag; 2006: Chapter 5.
178. Maxon HR. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med 1999;43(4):313-323.
179. Sgouros G, Kolbert KS, Sheikh A, et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 1241 PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004;45(8):1366-1372.
180. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am I Roentgenol Radium Ther Nucl Med 1962;87:171-182.
181. Sisson IC, Shulkin BL, Lawson S. Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retentions of 1311. I Nucl Med 2003;44(6):898-903.
182. Sisson IC, Carey IE. Thyroid carcinoma with high levels of function: treatment with (131) 1. I Nucl Med 2001;42(6):975-983.
183. Robbins RJ, Tuttle RM, Sonenberg M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001;11(9):865-869.
184. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. I Clin Endocrinol Metab 2006;91(3):926-932.
185. Luster M, Sherman SI, Skarulis MC, et al. Comparison of radiobiokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 2003;30:1371-1377.
186. Tuttle WK 3rd, Brown PH. Applying Nuclear Regulatory Commission guidelines to the release of patients treated with sodium iodine-131. J Nucl Med Technol 2000;28(4):275-279.
187. Grigsby PW, Siegel BA, Baker S, Eichling JO. Radiation exposure from outpatient radioactive iodine (1311) therapy for thyroid carcinoma. JAMA 2000;283(17):2272-2274.
188. Gangopadhyay KK, Sundram F, De P. Triggering radiation alarms after radioiodine treatment. BMJ 2006;333(7562):293-294.
189. Alexander C, Bader JB, Schaefer A, Fincke C, Kirsch C-M. Intermediate and longterm side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998;39:1551-1554.
190. Bohuslavizki KH, Klutmann S, Jenicke L, et al. Salivary gland protection by S-2-(3aminopropylamino) - ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial. Cancer Biother Radiopharm 1999;14(5):337-347.
191. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 1995;36(1):21-27.
192. Shepler TR, Sherman SI, Faustina MM, Busaidy NL, Ahmadi MA, Esmaeli B. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma. Ophthal Plast Reconstr Surg 2003;19(6):479-481.
193. Seidlin SM, Siegel E, Melamed S, Yalow AA. Occurrence of myeloid leukemia in patients with metastatic thyroid carcinoma following prolonged massive radioiodine therapy. Bull NYAcad Med 1955;31(5):410.
194. Seidlin SM, Siegal E, Yalow AA, Melamed S. Acute myeloid leukemia following prolonged iodine-131 therapy for metastatic thyroid carcinoma. Science 1956;123(3201):800-801.
195. Pochin E. Long-term hazards of radioiodine treatment of thyroid carcinoma. In: Hedinger C, ed. Thyroid Cancer. UICC Monograph Series. Vol 12. Berlin: SpringerVerlag; 1969:293-304.
196. Bakheet SM, Powe J, Hammami MM. Unilateral radioiodine breast uptake. Clin Nucl Med 1998;23(3):170-171.
197. Bakheet SM, Hammami MM. Patterns of radioiodine uptake by the lactating breast. Eur J Nucl Med 1994;21(7):604-608.
198. Li CI, Rossing MA, Voigt LF, Daling JR. Multiple primary breast and thyroid cancers: role of age at diagnosis and cancer treatments (United States). Cancer Causes Control 2000;11(9):805-811.
199. Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR, Vassilopoulou-Sellin R. The development of breast carcinoma in women with thyroid carcinoma. Cancer 2001;92(2):225-231.
200. Adjadj E, Rubino C, Shamsaldim A, Le MG, Schlumberger M, De Vathaire F. The risk of multiple primary breast and thyroid carcinomas. Cancer 2003;98(6):1309-1317.
201. Glanzmann C. Subsequent malignancies in patients treated with 131-iodine for thyroid cancer. Strahlenther Onkol 1992;168(6):337-343.
202. Schlumberger M, De Vathaire F, Ceccarelli C, et al. Exposure to radioactive iodine131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 1996;37(4):606-612.
203. Vini L, Hyer S, Al-Saadi A, Pratt B, Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J 2002;78(916):92-93.
204. Pacini F, Gasperi M, Fugazzola L, et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 1994;35(9):1418-1422.
205. Hyer S, Vini L, O'Connell M, Pratt B, Harmer C. Testicular dose and fertility in men following 1 (131) therapy for thyroid cancer. Clin Endocrinol (Oxf) 2002;56(6):755-758.
206. Ceccarelli C, Bencivelli W, Morciano D, Pinchera A, Pacini F. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab 2001;86(8):3512-3515.
207. Rall JE, Alpers JB, Lewallen CG, Sonenberg M, Berman M, Rawson RW. Radiation pneumonitis and fibrosis: a complication of radioiodine treatment of pulmonary metastases from cancer of the thyroid. J Clin Endocrinol Metab 1957;17(11):1263-1276.
208. Ali N, Sebastian C, Foley RR, et al. The management of differentiated thyroid cancer using 1231 for imaging to assess the need for 1311 therapy. Nucl Med Commun 2006;27(2):165-169.
209. Carr EA Jr, Dingledine WS, Beierwaltes W Ho Premature resort to x-ray therapy: a common error in treatment of carcinoma of the thyroid gland. J Lancet 1958;78(11):478-483.
210. Wong JB, Kaplan MM, Meyer KB, Pauker SG. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metab Clin North Am 1990;19(3):741-760.
211. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89(8):3668-3676.
212. Mazzaferri E. A randomized trial of remnant ablation-in search of an impossible dream? J Clin Endocrinol Metab 2004;89(8):3662-3664.
213. Haugen BR. Initial treatment of differentiated thyroid carcinoma. Rev Endocr Metab Disord 2000;1(3):139-145.
214. Taylor T, Specker B, Robbins J, et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 1998;129(8):622-627.
215. Cunningham MP, Duda RB, Recant W, Chmiel JS, Sylvester JA, Fremgen A. Survival discriminants for differentiated thyroid cancer. Am J Surg 1990;160(4):344-347.
216. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26(8):879-885.
217. Van Wyngaarden K, McDougall IR. Is serum thyroglobulin a useful marker for thyroid cancer in patients who have not had ablation of residual thyroid tissue? Thyroid 1997;7(3):343-346.
218. Kalinyak JE, McDougall IR. Whole-body scanning with radionuclides of iodine and the controversy of thyroid stunning. Nucl Med Commun 2004;25:883889.
219. Park H, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994;4:49-54.
220. Muratet J, Daver A, Minier JF, Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 1998;39:1546-1550.
221. Leger F, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998;25:242-246.
222. Cholewinski SP, Yoo KS, Klieger PS, O'Mara RE. Absence of thyroid stunning after diagnostic whole-body scanning with 185MBq 1311. J Nucl Med 2000;41(7):1198-1202.
223. Sisson J, Jamadar DA, Kazerooni EA, Giordano TJ, Carey JE, Spaulding SA. Treatment of micronodular metastases of papillary thyroid cancer: are tumors too small for effective irradiation from radioiodine? Thyroid 1999;8:215-221.
224. Pineda J, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80:1488-1492.
225. Schlumberger M, Mancusi F, Baudin E, Pacini F. 1311 therapy for elevated thyroglobulin levels. Thyroid 1997;7:273-276.
226. McDougall IR. Management of thyroglobulin positive/whole-body scan negative: is Tg positive/1311 therapy useful? J Endocrinol Invest 2001;24(3):194-198.
227. Fatourechi V, Hay ID, Iavedan H, Wiseman GA, Mullan BP, Gorman CA. Lack of impact of radioiodine therapy in Tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab 2002;87(4):1521-1526.
228. Wang W, Larson SM, Tuttle RM, et al. Resistance of 18f- fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 2001;11(12):1169-1175.
229. Karwowski J, Jeffrey RB, McDougall IR, Weigel RJ. Intraoperative ultrasonography improves identification of recurrent thyroid cancer. Surgery 2002;132:924-928.
230. Smit JW, Links TP, Hew JM, Goslings BM, Vielvoye GJ, Vermey A. [Embolization of skeletal metastases in patients with differentiated thyroid carcinoma]. Ned Tijdschr Geneeskd 2000;144(29):1406-1410.
231. Van Herle A J A, Agatep ML, Padua DN 3rd, et al. Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLARO 82 W-l) in vitro. J Clin Invest 1990;71:755-763.
232. Simon D, Korber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 2002;29(6):775-782.
233. Gruning T, Tiepolt C, Zophel K, Bredow J, Kropp I, Franke WG. Retinoic acid for redifferentiation of thyroid cancer-does it hold its promise? Eur I Endocrinol 2003;148(4):395-402.
234. Schraube P, Kimmig B, Zum Winkel K. [Lithium as an adjuvant in the radioiodine therapy of thyroid cancer]. Nuklearmedizin 1984;23(3):151-154.
235. Koong SS, Reynolds IC, Movius EG, et al. Lithium as a potential adjuvant to 1311 therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999;84(3):912-916.
236. Burgess J, Duffield A, Wilkinson BJ, et al. Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid. J Clin Endocrinol Metab 1997;82:345-348.
237. Loh KC. Familial nonmedullary thyroid carcinoma: a meta-review of case series. Thyroid 1997;7(1):107-113.
238. Houlston R. Genetic predisposition to non-medullary thyroid cancer. Nucl Med Commun 1998;19:911-913.
239. Malchoff CD, Malchoff DM. Familial nonmedullary thyroid carcinoma. Semin Surg Oncol 1999;16(1):16-18.
240. Alsanea O, Wada N, Ain K, et al. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery 2000;128(6):1043-1050; discussion 1050-1051.
241. Uchino S, Noguchi S, Kawamoto H, Yamashita H, Watanabe S, Shuto S. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg 2002;26(8):897-902.
242. Mello AM, Isaacs R, Petersen J, Kronenberger S, McDougall IR. Management of thyroid papillary carcinoma with radioiodine in a patient with end stage renal disease on hemodialysis. Clin Nucl Med 1994;19(9):776-781.
243. Holst JP, Burman KD, Atkins F, Umans JG, Jonklaas J. Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid 2005;15(12):1321-1331.
244. Kaptein EM, Levenson H, Siegel ME, Gadallah M, Akmal M. Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy. J Clin Endocrinol Metab 2000;85(9):3058-3064.
245. Heshmati HM, Fatourechi V, Van Heerden JA, Hay ID, Goellner JR. Thyroglossal duct carcinoma: report of 12 cases. Mayo Clin Proc 1997;72(4):315-319.
246. Peretz A, Leiberman E, Kapelushnik J, Hershkovitz E. Thyroglossal duct carcinoma in children: case presentation and review of the literature. Thyroid 2004;14(9):777-785.
247. Seoane JM, Cameselle-Teijeiro J, Romero MA. Poorly differentiated oxyphilic (Hurthle cell) carcinoma arising in lingual thyroid: a case report and review of the literature. Endocr Pathol 2002;13(4):353-360.
248. Miccoli P, Minuto MN, Galleri D, Puccini M, Berti P. Extent of surgery in thyroglossal duct carcinoma: reflections on a series of eighteen cases. Thyroid 2004;14(2):121-123.
249. Massine RE, Durning SJ, Koroscil TM. Lingual thyroid carcinoma: a case report and review of the literature. Thyroid 2001;11(12):1191-1196.
250. Mill WA, Gowing NF, Reeves B, Smithers DW. Carcinoma of the lingual thyroid treated with radioactive iodine. Lancet 1959;1(7063):76-79.
251. Kempers RD, Dockerty MB, Hoffman DL, Bartholomew LG. Struma ovarii-ascitic, hyperthyroid, and asymptomatic syndromes. Ann Intern Med 1970;72(6):883-893.
252. Navarro MD, Tan MA, Lovecchio JL, Hajdu SI. Case report: malignant struma ovarii. Ann Clin Lab Sci 2004;34(1):107-112.
253. Tokuda Y, Hatayama T, Sakoda K. Metastasis of malignant struma ovarii to the cranial vault during pregnancy. Neurosurgery 1993;33(3):515-518.
254. Checrallah A, Medlej R, Saade C, Khayat G, Halaby G. Malignant struma ovarii: an unusual presentation. Thyroid 2001;11(9):889-892.
255. McDougall I. Metastatic struma ovarii: the burden of truth. Clin Nucl Med 2006;31:321-324.
256. Nahn PA, Robinson E, Strassman M. Conservative therapy for malignant struma ovarii. A case report. J Reprod Med 2002;47(11):943-945.
257. Devaney K, Snyder R, Norris HJ, Tavassoli FA. Proliferative and histologically malignant struma ovarii: a clinicopathologic study of 54 cases. Int J Gynecol Pathol 1993;12(4):333-343.
258. Pardo-Mindan FI, Vazquez N. Malignant struma ovarii. Light and electron microscopic study. Cancer 1983;51(2):337-343.
259. McDougall IR, Krasne D, Hanbery JW, Collins JA. Metastatic malignant struma ovarii presenting as paraparesis from a spinal metastasis. J Nucl Med 1989;30(3):407-411.
260. Chan SW, Farrell KE. Metastatic thyroid carcinoma in the presence of struma ovarii. Med J Aust 2001;175(7):373-374.
261. Nikiforov Y, Gnepp DR, Fagin JA. Thyroid lesions in children and adolescents after the Chernobyl disaster: implications for the study of radiation tumorigenesis. J Clin Endocrinol Metab 1996;81(1):9-14.
262. Nikiforov YE, Erickson LA, Nikiforova MN, Caudill CM, Lloyd RV. Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol 2001;25(12):1478-1484.
263. Kuhel WI, Kuder DI, Santos-Buch CA. Poorly differentiated insular thyroid carcinoma. A case report with identification of intact insulae with fine needle aspiration biopsy. Acta Cytol 1998;42(4):991-997.
264. Decaussin M, Bernard MH, Adeleine P, et al. Thyroid carcinoma with distant metastases. A review of 11 cases with emphasis on the prognostic significance of the insular component. Am J Surg Pathol 2002;26:1007-1015.
265. Takeuchi Y, Daa T, Kashima K, Yokoyama S, Nakayama I, Noguchi S. Mutations of p53 in thyroid carcinoma with an insular component. Thyroid 1999;9(4):377-381.
266. Tallini G, Carcangiu ML, Rosai J. Oncocytic neoplasms of the thyroid gland. Acta Pathol Ipn 1992;42(5):305-315.
267. Watson RG, Brennan MD, Goellner JR, Van Heerden JA, McConahey WM, Taylor WF. Invasive Hiirthle cell carcinoma of the thyroid: natural history and management. Mayo Clin Proc 1984;59(12):851-855.
268. Stojadinovic A, Ghossein RA, Hoos A, et al. Hiirthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol 2001;19(10):2616-2625.
269. Lopez-Penabad L, Chiu AC, Hoff AO, et al. Prognostic factors in patients with Hiirthle cell neoplasms of the thyroid. Cancer 2003;97(5):1186-1194.
270. Gundry SR, Burney RE, Thompson NW, Lloyd R. Total thyroidectomy for Hiirthle cell neoplasm of the thyroid. Arch Surg 1983;118(5):529-532.
271. Dahl LD, Myssiorek D, Heller KS. Hiirthle cell neoplasms of the thyroid. Laryngoscope 2002;112(12):2178-2180.
272. Plotkin M, Hautzel H, Krause BJ, et al. Implication of 2-18fiuor-2-deoxyglucose positron emission tomography in the follow-up of Hurthle cell thyroid cancer. Thyroid 2002;12(2):155-161.
273. Wu Y. Differentiated carcinoma of the thyroid in children and adolescents. Ann Chir 2001;126(10):977-980.
274. Farahati J, Parlowsky T, Mader U, Reiners C, Bucsky P. Differentiated thyroid cancer in children and adolescents. Langenbecks Arch Surg 1998;383(3-4):235-239.
275. De Keyser LF, Van Herle AJ. Differentiated thyroid cancer in children. Head Neck Surg 1985;8(2):100-114.
276. Nagai G, Pitts W, Basso L, Cisco JA, McDougall IR. Scintigraphic "hot nodules" and thyroid carcinoma. Clin Nucl Med 1987;12:123-127.
277. Corrias A, Einaudi S, Chiorboli E, et al. Accuracy of fine needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: comparison with conventional clinical, laboratory, and imaging approaches. J Clin Endocrinol Metab 2001;86:4484-4488.
278. La Quaglia MP, Black T, Holcomb GW 3rd, et al. Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. Areport from the Surgical Discipline Committee of the Children's Cancer Group. J Pediatr Surg 2000;35(6):955-959; discussion 960.
279. Peretz A, Leiberman E, Kapelushnik J, Hershkovitz E. Thyroglossal duct carcinoma in children: case presentation and review of the literature. Thyroid 2004;14(9):777-785.
280. Nikiforov YE, Erickson LA, Nikiforova MN, Caudill CM, Lloyd RV. Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol 2001;25(12):1478-1484.
281. Hassoun AA, Hay ID, Goellner JR, Zimmerman D. Insular thyroid carcinoma in adolescents: a potentially lethal endocrine malignancy. Cancer 1997;79(5):1044-1048.
282. Ringel M, Levine MA. Current therapy for childhood thyroid cancer: optimal surgery and the legacy of King Pyrrhus, Ann Surg Oncol 2002;10:4-6.
283. Bal CS, Padhy AK, Kumar A. Clinical features of differentiated thyroid carcinoma in children and adolescents from a sub-Himalayan iodine-deficient endemic zone. Nucl Med Commun 2001;22(8):881-887.
284. Arici C, Erdogan O, Altunbas H, et al. Differentiated thyroid carcinoma in children and adolescents. Clinical characteristics, treatment and outcome of 15 patients. Horm Res 2002;57(5-6):153-156.
285. Kowalski LP, Goncalves Filho I, Pinto CA, Carvalho AL, De Camargo B. Long-term survival rates in young patients with thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2003;129(7):746-749.
286. Cady B. Presidential address: beyond risk groups-a new look at differentiated thyroid cancer. Surgery 1998;124(6):947-957.
287. Miccoli P, Antonelli A, Spinelli C, Ferdeghini M, Fallahi P, Baschieri I. Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. Arch Surg 1998;133(1):89-93.
288. Jarzab B, Handkiewicz-Junak D, Wloch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer 2005;12(4):773-803.
289. Zimmerman D, Hay ID, Gough IR, et al. Papillary thyroid cancer in children and adults: long-term follow-up of 1039 patients conservatively treated at one institute during three decades. Surgery 1988;104:1157-1166.
290. Park H-M, Perkins OW, Edmondson JW, et al. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994;4:49-54.
291. McDougall IR. 74MBq radioiodine 1311 does not prevent uptake of therapeutic doses of 1311 (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 1997;18(6):505-512.
292. Park HM. 1231: almost a designer radioiodine for thyroid scanning. J Nucl Med 2002;43(1):77-78.
293. Mandel SI, Shankar LK, Benard F, Yamamoto A, Alavi A. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2001;26(1):6-9.
294. Mazzaferri EI. Radioiodine and other treatments and outcomes. In: Braverman LE, Utiger RD, eds. Werner and Inbar's The Thyroid: A Fundamental and Clinical Text. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2000:904-929.
295. Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid 2002;12(8):683-702.
296. Haveman JW, Van Tol KM, Rouwe CW, Piers Do A, Plukker JT. Surgical experience in children with differentiated thyroid carcinoma. Ann Surg Oncol 2003;10(1):15-20.
297. Chow SM, Law SC, Mendenhall WM, et al. Differentiated thyroid carcinoma in childhood and adolescence: clinical course and role of radioiodine. Pediatr Blood Cancer 2004;42(2):176-183.
298. Grigsby PW, Gal-or A, Michalski JM, Doherty GM. Childhood and adolescent thyroid carcinoma. Cancer 2002;95(4):724-729.
299. Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 1998;39(9):1531-1536.
300. Anger K, Feine U. Thyroid carcinoma in childhood. Prog Pediatr Surg 1983;16:39-42.
301. Schlumberger M. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306.
302. Sisson JC, Carey JE. Thyroid carcinoma with high levels of function: treatment with (131) 1. J Nucl Med 2001;42(6):975-883.
303. Sisson JC, Shulkin BL, Lawson S. Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retentions of 1311. J Nucl Med 2003;44(6):898-903.
304. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84(11):3877-3885.
305. Lorcansky S, Herzovich V, Qualey RR, Tuttle RM. Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer. J Clin Endocrinol Metab 2005;90(12):6553-6555.
306. Grigsby PW, Siegel BA, Baker S, Eichling JO. Radiation exposure from outpatient radioactive iodine (1311) therapy for thyroid carcinoma. JAMA 2000;283(17):2272-2274.
307. Sisson JC, Giordano TJ, Jamadar DA, et al. 131-1treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer 1996;78(10):21842192.
308. Rosenbaum RC, Johnston GS, Valente WA. Frequency of hepatic visualization during 1-131 imaging for metastatic thyroid carcinoma. Clin Nucl Med 1988;13(9):657-660.
309. Carlisle M, Lu C, McDougall IR. The interpretation of 1311 scans in the evaluation of thyroid cancer, with an emphasis on false positive findings. Nucl Med Commun 2003;24:715-735.
310. Vini L, Hyer S, Al-Saadi A, Pratt B, Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J 2002;78(916):92-93.
311. Casara D. Rubello D, Saladini G, et al. Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: potential risks and recommendations. Eur J Nucl Med 1993;20(3):192-194.
312. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo I. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 1995;36(1):21-27.
313. Ayala C, Navarro E, Rodriguez IR, Silva H, Venegas E, Astorga R. Conception after iodine-131 therapy for differentiated thyroid cancer. Thyroid 1998;8(11):10091011.
314. Dottorini ME, Vignati A, Mazzucchelli L, Lomuscio G, Colombo I. Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. J Nucl Med 1997;38(5):669-675.
315. Hyer S, Vini L, O'Connell M, Pratt B, Harmer C. Testicular dose and fertility in men following 1 (131) therapy for thyroid cancer. Clin Endocrinol (Oxf) 2002;56(6):755-758.
316. RaIl JE, Alpers JB, Lewallen CG, Sonenberg M, Berman M, Rawson RW. Radiation pneumonitis and fibrosis: a complication of radioiodine treatment of pulmonary metastases from cancer of the thyroid, I Clin Endocrinol Metab 1957;17(11):1263-1276.
317. Alessandri AI, Goddard KI, Blair GK, Fryer CI, Schultz KR. Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. Med Pediatr Oncol 2000;35(1):41-46.
318. Lee YM, Lo CY, Lam KY, Wan KY, Tam PK. Well-differentiated thyroid carcinoma in Hong Kong Chinese patients under 21 years of age: a 35-year experience. J Am ColI Surg 2002;194(6):711-716.
319. Buckwalter JA, Thomas CG, Freeman JB. Is childhood thyroid cancer a lethal disease? Ann Surg 1975;181(5):632-639.
320. Jarzab B, Handkiewicz Iunak D, Wloch J, et al. Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. Eur J Nuel Med 2000;27(7):833-841.
321. Zettinig G, Kaserer K, Passler C, Flores JA, Niederle B, Dudczak R. Advanced insular thyroid carcinoma in a fourteen-year-old girl: twenty-four years of follow-up. Thyroid 2000;10(5):435-437.
322. Morris PC. Thyroid cancer complicating pregnancy. Obstet Gynecol Clin North Am 1998;25(2):401-405.
323. Gharib H. Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and effect. Mayo Clin Proc 1994;69:44-49.
324. Rosen IB, Walfish PG. Pregnancy as a predisposing factor in thyroid neoplasia. Arch Surg 1986;121(11):1287-1290.
325. Marley EF, Oertel YC. Fine-needle aspiration of thyroid lesions in 57 pregnant and postpartum women. Diagn Cytopathol 1997;16(2):122-125.
326. Goldman MH, Tisch B, Chattock AG. Fine-needle biopsy of a solitary thyroid nodule arising during pregnancy. J Med Soc N J 1983;80(7):525-526.
327. Moosa M, Mazzaferri EL. Outcome of differentiated thyroid cancer diagnosed in pregnant women. J Clin Endocrinol Metab 1997;82(9):2862-2866.
328. Brodsky JB, Cohen EN, Brown BW Jr, Wu ML, Whitcher C. Surgery during pregnancy and fetal outcome. Am J Obstet Gynecol 1980;138(8):1165-1167.
329. Driggers RW, Kopelman IN, Satin AJ. Delaying surgery for thyroid cancer in pregnancy. A case report. J Reprod Med 1998;43(10):909-912.
330. Hochman M, Fee WE Jr. Thyroidectomy under local anesthesia. Arch Otolaryngol Head Neck Surg 1991;117(4):405-407.
331. Hisham AN, Aina EN. Areappraisal of thyroid surgery under local anaesthesia: back to the future? ANZ J Surg 2002;72(4):287-289.
332. Mandel SJ. Hypothyroidism and chronic autoimmune thyroiditis in the pregnant state: maternal aspects. Best Pract Res Clin Endocrinol Metab 2004;18(2):213224.
333. McDougall IR, Maclin N. Hypothyroid women need more thyroxine when pregnant. J Fam Pract 1995;41(3):238-240.
334. Kaplan MM. Management of thyroxine therapy during pregnancy. Endocr Pract 1996;2(4):281-286.
335. Campbell NR, Hasinoff BB, Stalts H, Rao B, Wong NC. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann Intern Med 1992;117(12):1010-1013.
336. Shakir KM, Chute IP, Aprill BS, Lazarus AA. Ferrous sulfate-induced increase in requirement for thyroxine in a patient with primary hypothyroidism. South Med J 1997;90(6):637-639.
337. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26(8):879-885.
338. Wapnir IL, Van De Rijn M, Nowels K, et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab 2003;88(4):1880-1888.
339. Dohan O, De La Vieja A, Paroder V, et al. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 2003;24(1):48-77.
340. Bakheet SM, Hammami MM. Patterns of radioiodine uptake by the lactating breast. Eur J Nucl Med 1994;21(7):604-608.
341. Bakheet SM, Powe J, Hammami MM. Unilateral radioiodine breast uptake. Clin Nucl Med 1998;23(3):170-171.
342. Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR, Vassilopoulou-Sellin R. The development of breast carcinoma in women with thyroid carcinoma. Cancer 2001;92(2):225-231.
343. Barrington SF, O'Doherty MJ, Kettle AG, et al. Radiation exposure of the families of outpatients treated with radioiodine (iodine-13l) for hyperthyroidism. Eur J Nucl Med 1999;26(7):686-692.
344. Choe W, McDougall JR. Thyroid cancer in pregnant women: diagnostic and therapeutic management. Thyroid 1994;4(4):433-435.
345. Wemeau JL, Do Cao C. [Thyroid nodule, cancer and pregnancy]. Ann Endocrinol (Paris) 2002;63(5):438-442.
346. Schlumberger M, De Vathaire F, Ceccarelli C, et al. Exposure to radioactive iodine131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 1996;37(4):606-612.
347. Chow SM, Yau S, Lee SH, Leung WM, Law SC. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: no deleterious effect after radioactive iodine treatment. Int J Radiat Oncol BioI Phys 2004;59(4):992-1000.
348. Vini L, Hyer S, Al-Saadi A, Pratt B, Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J 2002;78(916):92-93.
349. Briere J, Philippon B. Absorbed dose to ovaries or uterus during a 131I-therapeutic of cancer or hyperthyroidism: comparison between in vivo measurements by TLD and calculations. Int J Appl Radiat Isot 1979;30(10):643-646.
350. Philippon B, Briere J. Absorbed dose to ovaries and uterus during 131I-treatment of hyperthyroidism: comparison between in vivo TLD measurements and calculations. Health Phys 1979;36(6):727-729.
351. Ayala C, Navarro E, Rodriguez JR, Silva H, Venegas E, Astorga R. Conception after iodine-131 therapy for differentiated thyroid cancer. Thyroid 1998;8(11):10091011.
352. Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, Larsen P Ro Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med 2004;351(3):241-249.
353. Krassas GE. Thyroid disease and female reproduction. Fertil Steril 2000;74(6):1063-1070.
354. Kobayashi K, Tanaka Y, Ishiguro S, Mori T. Rapidly growing thyroid carcinoma during pregnancy. J Surg Oncol 1994;55(1):61-64.
355. Vini L, Hyer S, Pratt B, Harmer C. Management of differentiated thyroid cancer diagnosed during pregnancy. Eur J Endocrinol 1999;140(5):404-406.
356. Lazarus JH. Guidelines for the use of radioiodine in the management of hyperthyroidism: a summary. Prepared by the Radioiodine Audit Subcommittee of the Royal College of Physicians Committee on Diabetes and Endocrinology, and the Research Unit of the Royal College of Physicians. J R ColI Physicians Lond 1995;29(6):464-469.
357. Stoffer SS, Hamburger JI. Inadvertent 1311therapy for hyperthyroidism in the first trimester of pregnancy. J Nucl Med 1976;17(02):146-149.
358. Fisher WD, Voorhess ML, Gardner LI. Congenital hypothyroidism in infant following maternal 1-131 therapy with a review of hazards of environmental radioisotope contamination. J Pediatr 1963;62:132-146.
359. Berg GE, Nystrom EH, Jacobsson L, et al. Radioiodine treatment of hyperthyroidism in a pregnant women. J Nucl Med 1998;39(2):357-361.
360. Evans PM, Webster J, Evans WD, Bevan JS, Scanlon MF. Radioiodine treatment in unsuspected pregnancy. Clin Endocrinol (Oxf) 1998;48(3):281-283.
361. Agrawal P, Ogilvy-Stuart A, Lees C. Intrauterine diagnosis and management of congenital goitrous hypothyroidism. Ultrasound Obstet Gynecol 2002;19(5):501505.
362. Berlin I. Iodine-131 and the pregnant patient. AJR Am J Roentgenol 2001;176(4):869-871.
363. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U. S., 1985-1995 [see comments]. Cancer 1998;83(12):2638-2648.
364. Wenisch H J W, Wagner RH, Schumm-Draeger PM, Encke A. Cytostatic drug therapy in anaplastic thyroid carcinoma. World J Surg 1986;10(5):762-769.
365. Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 1999;16(1):64-69.
366. Pasieka JI. Anaplastic thyroid cancer. Curr Opin Oncol 2003;15(1):78-83.
367. Crile G Jr, Wilson DH. Transformation of a low grade papillary carcinoma of the thyroid to an anaplastic carcinoma after treatment with radioiodine. Surg Gynecol Obstet 1959;108(3):357-360.
368. Vescini F, Di Gaetano P, Vigna E, Pascoli A, Cacciari M. Anaplastic thyroid carcinoma in a 49-year-old woman with a long-standing goiter. A case report. Minerva Endocrinol 2000;25(3-4):81-83.
369. Pierie JP, Muzikansky A, Gaz RD, Faquin WC, Ott MJ. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 2002;9(1):57-64.
370. Lam KY, Lo CY, Chan KW, Wan KY. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann Surg 2000;231(3):329-338.
371. Ratnatunga PC, Amarasinghe SC, Ratnatunga NV. Changing patterns of thyroid cancer in Sri Lanka. Has the iodination programme helped? Ceylon Med J 2003;48(4):125-128.
372. Lo CY, Lam KY, Wan KY. Anaplastic carcinoma of the thyroid. Am J Surg 1999;177(4):337-339.
373. Heron DE, Karimpour S, Grigsby PW. Anaplastic thyroid carcinoma: comparison of conventional radiotherapy and hyperfractionation chemoradiotherapy in two groups. Am J Clin Oncol 2002;25(5):442-446.
374. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130(6):1028-1034.
375. Lee SY, Chang SE, Bae GY, et al. Carcinoma erysipeloides associated with anaplastic thyroid carcinoma. Clin Exp Dermatol 2001;26(8):671-673.
376. Villa ML, Mukherjee JJ, Tran NQ, Cheah WK, Howe HS, Lee KG. Anaplastic thyroid carcinoma with destructive thyrotoxicosis in a patient with preexisting multinodular goiter. Thyroid 2004;14(3):227-230.
377. Aldinger KA, Samaan NA, Ibanez M, Hill C S Jr. Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer 1978;41(6):2267-2275.
378. Haigh PI, Ituarte PH, Wu HS, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001;91(12):2335-2342.
379. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990;66(2):321-330.
380. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005;103(7):13301335.
381. Simpson WJ. Anaplastic thyroid carcinoma: a new approach. Can J Surg 1980;23(1):25-27.
382. Kim JH, Leeper RD. Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination adriamycin and radiation therapy. Anew approach. Cancer 1983;52(6):954-957.
383. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987;60(10):2372-2375.
384. De Besi P, Busnardo B, Toso S, et al. Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 1991;14(6):475-480.
385. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000;10(7):587-594.
386. Kasai N, Sakamoto A, Uchida M. A combined modality for anaplastic large-cell carcinoma of the thyroid. Auris Nasus Larynx 1985;12(suppl2):S72-74.
387. Besic N, Auersperg M, Us-Krasovec M, Golouh R, Frkovic-Grazio S, Vodnik A. Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol 2001;27(3):260-264.
388. Veness MJ, Porter GS, Morgan GJ. Anaplastic thyroid carcinoma: dismal outcome despite current treatment approach. ANZ J Surg 2004;74(7):559-562.
389. Donovan JK, Ilbery PI. Metastases from anaplastic thyroid carcinoma responding to radioiodine. Clin Radiol 1971;22(3):401-404.
390. Schmutzler C, Kohrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000;10(5):393-406.
391. Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol 1985;83(2):135-158.
392. Iunor EI, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 1992;18(2):83-88.
393. Kobayashi T, Asakawa H, Umeshita K, et al. Treatment of37 patients with anaplastic carcinoma of the thyroid. Head Neck 1996;18(1):36-41.
394. Casterline PF, Jaques DA, Blom H, Wartofsky I. Anaplastic giant and spindle-cell carcinoma of the thyroid: a different therapeutic approach. Cancer 1980;45(7):1689-1692.
395. Kihara M, Miyauchi A, Yamauchi A, Yokomise H. Prognostic factors of anaplastic thyroid carcinoma. Surg Today 2004;34(5):394-398.
396. Donis-Keller H. The RET proto-oncogene and cancer. J Intern Med 1995;238(4):319-325.
397. Bachelot A, Lombardo F, Baudin E, Bidart JM, Schlumberger M. Inheritable forms of medullary thyroid carcinoma. Biochimie 2002;84(1):61-66.
398. Caillou B, Rougier P, Schlumberger M, Talbot M, Parmentier C. Value ofimmunohistochemistry in the study of medullary cancer of the thyroid. Implications of the results for the concept of the APUD system and of apudomas. Bull Cancer 1984;71(2):140-144.
399. Kebebew E, Ituarte P H G, Siperstein AE, Duh Q-Y, Clark OH. Medullary thyroid carcinoma. Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000;88:1139-1148.
400. Ponder BA, Finer N, Coffey R, et al. Family screening in medullary thyroid carcinoma presenting without a family history. Q J Med 1988;67(252):299-308.
401. Ali SZ, Teichberg S, Attie IN, Susin M. Medullary thyroid carcinoma metastatic to breast masquerading as infiltrating lobular carcinoma. Ann Clin Lab Sci 1994;24(5):441-447.
402. Jee MS, Chung YI, Lee MW, Choi JH, Moon KC, Koh JK. Cutaneous metastasis from medullary carcinoma of thyroid gland. Clin Exp Dermatol 2003;28(6):670-671.
403. Ordonez NG, Samaan NA. Medullary carcinoma of the thyroid metastatic to the skin: report of two cases. J Cutan Pathol 1987;14(4):251-254.
404. Puxeddu E, Fagin JA. Genetic markers in thyroid neoplasia. Endocrinol Metab Clin North Am 2001;30(2):493-513, x.
405. Graze K, Spiler IJ, Tashjian AH Jr, et al. Natural history of familial medullary thyroid carcinoma: effect of a program for early diagnosis. N Engl J Med 1978;299(18):980-985.
406. Melvin K, Tashjian AH Jr. The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid. Proc Nat! Acad Sci USA 1968;59:1216-1222.
407. Melvin KE, Tashjian AH Jr, Miller HH. Studies in familial (medullary) thyroid carcinoma. Recent Prog Horm Res 1972;28:399-470.
408. Elisei R, Bottici V, Luchetti F, et al Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10, 864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004;89(1):163-168.
409. Iacobone M, Niccoli-Sire P, Sebag F, De Micco C, Henry JF. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels. World J Surg 2002;26(8):886-890.
410. Niccoli P, Conte-Devolx B, Lejeune PI, et al. [Hypercalcitoninemia in conditions other than medullary cancers of the thyroid]. Ann Endocrinol (Paris) 1996;57(1):15-21.
411. Schlumberger M, Pacini F. Medullary thyroid carcinoma. In: Schlumberger M, Pacini F, eds. Thyroid Tumors. Paris: Nucleon; 1999:267-299;301-307.
412. Vierhapper H, Nowotny P, Bieglmayer Ch, Gessl A. Prevalence of hyper gastrinemia in patients with hyper- and hypothyroidism: impact for calcitonin? Horm Res 2002;57(3-4):85-89.
413. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16(2):109-142.
414. Melvin KE, Tashjian AH Jr, Cassidy CE, Givens JR. Cushing's syndrome caused by ACTH- and calcitonin-secreting medullary carcinoma of the thyroid. Metabolism 1970;19(10):831-838.
415. Mure A, Gicquel C, Abdelmoumene N, et al. Cushing's syndrome in medullary thyroid carcinoma. J Endocrinol Invest 1995;18(3):180-185.
416. Smallridge RC, Bourne K, Pearson BW, Van Heerden JA, Carpenter PC, Young WF. Cushing's syndrome due to medullary thyroid carcinoma: diagnosis by proopiomelanocortin messenger ribonucleic acid in situ hybridization. J Clin Endocrinol Metab 2003;88(10):4565-4568.
417. Brandi M, Gagel RF, Angeli A, et al. Consensus: guidelines for diagnosis and therapy of MEN Type 1 and 2. J Clin Endocrinol Metab 2001;86:5658-5671.
418. NCCN. Practice Guidelines in Oncology. V. 1.2003. Thyroid Cancer: Medullary Cancer. CD available from National Comprehensive Cancer Network; 2004.
419. Yip L, Cote GJ, Shapiro SE, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 2003;138(4):409-416; discussion 416.
420. Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 2003;134(6):890-899; discussion 899-901.
421. Niccoli-Sire P, Murat A, Rohmer V, et al. When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RETmutations? Surgery 2003;134(6):1029-1036; discussion 1036-1037.
422. Machens A, Niccoli-Sire P, Hoegel I, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003;349(16):1517-1525.
423. Pender S, Little DM, Burke P, Broe P. Treatment of medullary carcinoma of the thyroid by laryngo-pharyngo-oesophagectomy: a case report. Ir J Med Sci 1992;161(7):450-451.
424. Saad MF, Guido JJ, Samaan NA. Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1983;57(1):124-128.
425. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 2001;91(9):1797-1808.
426. Bellantone R, Boscherini M, Lombardi CP, Alesina PF. Medullary thyroid carcinoma: surgical management of primary tumor and loco regional recurrence. Rays 2000;25(2):267-271.
427. Pollinger B, Duhmke E. External radiotherapy of thyroid cancer. Onkologie 2001;24(2):134-138.
428. Simpson WI, Palmer JA, Rosen IB, Mustard RA. Management of medullary carcinoma of the thyroid. Am J Surg 1982;144(4):420-422.
429. Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P, Sarrazin D. External radiotherapy in thyroid cancers. Cancer 1985;55(suppl 9):2062-2071.
430. Sarrazin D, Fontaine F, Rougier P, et al. [Role of radiotherapy in the treatment of medullary cancer of the thyroid]. Bull Cancer 1984;71(3):200-208.
431. Hoefnagel CA, Delprat CC, Valdes Olmos RA. Role of 131Imetaiodobenzylguanidine therapy in medullary thyroid carcinoma. J Nucl BioI Med 1991;35(4):334336.
432. Castellani MR, Alessi A, Savelli G, Bombardieri E. The role of radionuclide therapy in medullary thyroid cancer. Tumori 2003;89(5):560-562.
433. Wiseman GA, Kvols LK. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med 1995;25(3):272-278.
434. Shapiro B. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks. Q J Nucl Med 1995;39(4 suppl1):150-155.
435. Juweid ME, Hajjar G, Stein R, et al. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F (ab) 2 anticarcinoembryonic antigen MAb and AHSCR. J Nucl Med 2000;41(1):93-103.
436. 111In- DTPA-D-Phel-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med 2000;41(4):636-642.
437. Yang KP, Liang YF, Samaan NA. Intrinsic drug resistance in a human medullary thyroid carcinoma cell line: association with overexpression of mdrl gene and low proliferation fraction. Anticancer Res 1991;11(3):1065-1068.
438. Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 2000;83(6):715-718.
439. Ahlman H, Tisell LE. The use of a long-acting somatostatin analogue in the treatment of advanced endocrine malignancies with gastrointestinal symptoms. Scand J Gastroenterol 1987;22(8):938-942.
440. Lanzi C, Cassinelli G, Cuccuru G, Zanchi C, Laccabue D, Zunino F. RET/PTC oncoproteins: molecular targets of new drugs. Tumori 2003;89(5):520-522..
441. Zhang J, Dai W, Lian X, et al. [Detection of remnants after removal of medullary thyroid carcinoma]. Zhonghua Wai Ke Za Zhi 2000;38(1):19-21.
442. Adams BK, Fataar A, Byrne MJ, Levitt NS, Madey PJ. Pentavalent technetium-99m (V)-DMSA uptake in a pheochromocytoma in a patient with Sipple's syndrome. J Nucl Med 1990;31(1):106-108.
443. 18FFDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca 2003;30(1):22-25.
444. Cook G, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET with 18-fluoro-2-deoxyglucose and carbon-It methionine. Eur J Nucl Med 1999;26:1363-1378.
445. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDGPET imaging: physiologic and benign variants. Radiographies 1999;19(1):61-77; quiz 150-151.
446. Bhattacharyya N. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol Clin North Am 2003;128:115-125.
447. Sirota DK, Segal RL. Primary lymphomas of the thyroid gland. JAMA 1979;242(16):1743-1746.
448. Soltes SF. Primary malignant lymphoma of the thyroid. Ear Nose Throat J 1981;60(3):131-135.
449. Matsuzuka F, Miyauchi A, Katayama S, et al. Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. Thyroid 1993;3(2):93-99.
450. Schwarze EW, Papadimitriou C. Malignant lymphomas of the thyroid gland (author's transl). Verh Dtsch Ges Pathol 1977;61:328-335.
451. Devine RM, Edis AJ, Banks PM. Primary lymphoma of the thyroid: a review of the Mayo Clinic experience through 1978. World J Surg 1981;5(1):33-38.
452. Fonseca E, Sambade C. Primary lymphomas of the thyroid gland: a review with emphasis on diagnostic features. Arch Anat Cytol Pathol 1998;46(1-2):94-99.
453. Detweiler RE, Katz RL, Alapat C, El-Naggar A, Ordonez N. Malignant lymphoma of the thyroid: a report of two cases diagnosed by fine-needle aspiration. Diagn Cytopathol 1991;7(2):163-171.
454. Ishikawa H, Tamaki Y, Takahashi M, et al. Comparison of primary thyroid lymphoma with anaplastic thyroid carcinoma on computed tomographic imaging. Radiat Med 2002;20(1):9-15.
455. Chander S, Zingas AP, Bloom DA, Zak IT, Ioyrich RN, Getzen TM. Positron emission tomography in primary thyroid lymphoma. Clin Nucl Med 2004;29(9):572-573.
456. Yasuda S, Ide M, Takagi S, Shohtsu A. [Cancer screening with whole-body FDG PET]. Kaku Igaku 1996;33(10):1065-1071.
457. Yasuda S, Shohtsu A, Ide M, et al. Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology 1998;207:775-778.
458. Thieblemont C, Mayer A, Dumontet C, et al. Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab 2002;87(1):105-111.
459. Sippel RS, Gauger PG, Angelos P, Thompson NW, Mack E, Chen H. Palliative thyroidectomy for malignant lymphoma of the thyroid. Ann Surg Oncol 2002;9(9):907-911.
460. Willis R. Metastatic tumors in the thyroid. Am J Pathol 1931;7:187-208.
461. Shimaoka K, Sokal J, Pickren J. Metastatic neoplasms in the thyroid gland. Cancer 1962;15:557-565.
462. McCabe D, Farrar WB, Petkov TM, Finkelmeier W, O'Dwyer P, James A. Clinical and pathologic correlations in disease metastatic to the thyroid gland. Am J Surg 1985;150:519-523.
463. Nakhjavani MK, Gharib H, Goellner JR, Van Heerden JA. Metastasis to the thyroid gland. A report of 43 cases. Cancer 1997;79(3):574-578.
464. Kihara M, Yokomise H, Yamauchi A. Metastasis of renal cell carcinoma to the thyroid gland 19 years after nephrectomy: a case report. Auris Nasus Larynx 2004;31(1):95-100.
465. Pereira Arias JG, Acinas Garcia O, Escobal Tamayo V, et al. [Late metastasis in thyroid gland after nephrectomy for renal clear cell carcinoma]. Aetas Urol Esp 1995;19(6):468-472.
466. Michelow PM, Leiman G. Metastases to the thyroid gland: diagnosis by aspiration cytology. Diagn Cytopathol 1995;13(3):209-213.
467. Wood K, Vini L, Harmer C. Metastases to the thyroid gland: the Royal Marsden experience. Eur J Surg Oncol 2004;30(6):583-588.
468. De Ridder M, Sermeus AB, Urbain D, Storme GA. Metastases to the thyroid gland: a report of six cases. Eur J Intern Med 2003;14(6):377-379.
469. Ahuja AT, King W, Metreweli C. Role of ultrasonography in thyroid metastases. Clin Radiol 1994;49(9):627-629.
470. Chung S, Kim E-K, Kim JH, et al. Sonographic findings of metastatic disease to the thyroid. Yonsei Med J 2001;42:411-417.
471. McDougall I. Management of Thyroid Cancer and Related Nodular Diseases. London: Springer-Verlag; 2006: Chapter 12.
472. Haugen B, Nawaz S, Cohn A, et al. Secondary malignancy of the thyroid gland: a case report and review of the literature. Thyroid 1994;4:297-300.
473. Ro JY, Guerrieri C, El-Naggar AK, Ordonez NG, Sorge JG, Ayala AG. Carcinomas metastatic to follicular adenomas of the thyroid gland. Report of two cases. Arch Pathol Lab Med 1994;118(5):551-556.
474. Heffess CS, Wenig BM, Thompson LD. Metastatic renal cell carcinoma to the thyroid gland: a clinicopathologic study of 36 cases. Cancer 2002;95(9):1869-1878.
475. Ericsson M, Biorklund A, Cederquist E, Ingemansson S, Akerman M. Surgical treatment of metastatic disease in the thyroid gland. J Surg Oncol 1981;17(1):15-23.
476. Gambhir S, Czernin J, Schwimmer J, Silverman D H S, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S-93S.
477. Goerres G. PET and PET/CTof tumors with an unknown primary. In: van Schulthess GK, ed. Clinical Molecular Anatomic Imaging. Philadelphia: Lippincott Williams & Wilkins; 2003:284-290.
478. May M, Marusch F, Kaufmann O, et al. [Solitary renal cell carcinoma metastasis to the thyroid gland-a paradigm of metastasectomy?]. Chirurg 2003;74(8):768-774.
479. Benoit L, Favoulet P, Arnould L, et al. [Metastatic renal cell carcinoma of the thyroid gland: about seven cases and review of the literature]. Ann Chir 2004;129(4):218-223.